|Publication status||Published - 20 May 2014|
Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced esophagogastric adenocarcinoma.
T.S. Waddell, I. Chau, C. Peckitt, D. Gonzalez, A. Wotherspoon, B. Patel, G.W. Middleton, J. Wadsley, D. Ferry, W. Mansoor, T.D.L. Crosby, F.Y. Coxon, D. Smith, J.S. Waters, T. Iveson, S. Falk, S. Slater, A.F.C. Okines, D. Cunningham
Research output: Contribution to conference › Other › peer-review